EA200870327A1 - IMPROVED PROCARE OF ANALOGUES SS-1065 - Google Patents
IMPROVED PROCARE OF ANALOGUES SS-1065Info
- Publication number
- EA200870327A1 EA200870327A1 EA200870327A EA200870327A EA200870327A1 EA 200870327 A1 EA200870327 A1 EA 200870327A1 EA 200870327 A EA200870327 A EA 200870327A EA 200870327 A EA200870327 A EA 200870327A EA 200870327 A1 EA200870327 A1 EA 200870327A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- prodrug
- prodrugs
- analogues
- cytotoxic
- protecting group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Описаны пролекарства аналогов противоопухолевого антибиотика СС-1065, содержащие способную расщепляться защитную группу, содержащую группу сульфоновой кислоты, которая включает в себя фенилкарбамат, где указанная защитная группа обеспечивает пролекарству повышенную растворимость в воде по сравнению с незащищенным пролекарством и где пролекарство содержит такой фрагмент, как сульфид или дисульфид, который может соединяться с реагентом связывания клеток, таким как антитело. Описано также терапевтическое применение таких пролекарственных конъюгатов; такие пролекарства цитотоксических агентов обладают терапевтически полезным действием, поскольку они могут доставлять цитотоксические пролекарства к специфическим клеточным популяциям для ферментативного превращения в цитотоксическое лекарственное средство целевым образом.Prodrugs of analogues of the antitumor antibiotic SS-1065 are described, containing a cleavable protecting group containing a sulfonic acid group, which includes phenylcarbamate, wherein said protecting group provides the prodrug with increased solubility in water compared to an unprotected prodrug and where the prodrug contains a fragment such as sulfide or a disulfide that can bind to a cell binding reagent, such as an antibody. The therapeutic use of such prodrug conjugates is also described; such prodrugs of cytotoxic agents have a therapeutically beneficial effect because they can deliver cytotoxic prodrugs to specific cell populations for enzymatic conversion into a cytotoxic drug in a targeted manner.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06290379A EP1832577A1 (en) | 2006-03-07 | 2006-03-07 | Improved prodrugs of CC-1065 analogs |
PCT/IB2007/000521 WO2007102069A1 (en) | 2006-03-07 | 2007-03-06 | Improved prodrugs of cc-1065 analogs |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200870327A1 true EA200870327A1 (en) | 2009-02-27 |
Family
ID=36679356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200870327A EA200870327A1 (en) | 2006-03-07 | 2007-03-06 | IMPROVED PROCARE OF ANALOGUES SS-1065 |
Country Status (18)
Country | Link |
---|---|
US (2) | US8012978B2 (en) |
EP (2) | EP1832577A1 (en) |
JP (1) | JP2009529030A (en) |
KR (1) | KR20080106919A (en) |
AR (1) | AR059767A1 (en) |
AU (1) | AU2007222123A1 (en) |
BR (1) | BRPI0708654A2 (en) |
CA (1) | CA2642870A1 (en) |
DO (1) | DOP2007000041A (en) |
EA (1) | EA200870327A1 (en) |
IL (1) | IL193673A0 (en) |
MA (1) | MA30322B1 (en) |
MX (1) | MX2008011431A (en) |
NO (1) | NO20083910L (en) |
PE (1) | PE20080691A1 (en) |
TW (1) | TW200813028A (en) |
UY (1) | UY30190A1 (en) |
WO (1) | WO2007102069A1 (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
ATE446317T1 (en) | 2001-05-11 | 2009-11-15 | Ludwig Inst For Cancer Res Ltd | SPECIFIC BINDING PROTEINS AND THEIR USE |
US6756397B2 (en) * | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
JP5622390B2 (en) | 2006-07-18 | 2014-11-12 | サノフイ | Anti-EPHA2 antagonist antibody for cancer treatment |
JP5276017B2 (en) * | 2007-01-25 | 2013-08-28 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Use of anti-EGFR antibodies in the treatment of EGFR mutant mediated diseases |
CN101688229B (en) * | 2007-03-15 | 2013-06-12 | 路德维格癌症研究所 | Treatment method using EGFR antibodies and SRC inhibitors and related formulations |
US9901567B2 (en) | 2007-08-01 | 2018-02-27 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
CN101896503B (en) | 2007-08-14 | 2018-05-22 | 路德维格癌症研究所有限公司 | The monoclonal antibody 175 and its derivative and purposes of targeting EGF receptor |
US20090155289A1 (en) * | 2007-11-01 | 2009-06-18 | Steve Roberts | Furin-cleavable peptide linkers for drug-ligand conjugates |
ES2647317T3 (en) | 2008-11-03 | 2017-12-20 | Syntarga B.V. | Analogs of CC-1065 and its conjugates |
FR2947269B1 (en) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | NEW ANTICANCER COMPOUNDS |
FR2949469A1 (en) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | ANTICANCER DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
UY32914A (en) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | ANTIBODIES SPECIFICALLY USED TO THE EPHA2 RECEIVER |
TW201117814A (en) | 2009-10-02 | 2011-06-01 | Sanofi Aventis | New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody |
DK3108886T3 (en) * | 2010-04-21 | 2020-08-10 | Syntarga Bv | Conjugates of CC-1065 analogs and bifunctional linkers |
FR2963007B1 (en) | 2010-07-26 | 2013-04-05 | Sanofi Aventis | ANTICANCER DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
EP2830614B1 (en) * | 2012-03-30 | 2017-04-26 | The Scripps Research Institute | Cyclic prodrugs of duocarmycin analogs |
PL2872157T3 (en) | 2012-07-12 | 2020-07-13 | Hangzhou Dac Biotech Co., Ltd | Conjugates of cell binding molecules with cytotoxic agents |
ES2701076T3 (en) | 2012-11-24 | 2019-02-20 | Hangzhou Dac Biotech Co Ltd | Hydrophilic linkers and their uses for the conjugation of drugs to molecules that bind to cells |
US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
KR20160099725A (en) | 2014-01-10 | 2016-08-22 | 신톤 바이오파머슈티칼즈 비.브이. | Duocarmycin adcs for use in treatment of endometrial cancer |
EP3069735B1 (en) | 2014-01-10 | 2018-03-14 | Synthon Biopharmaceuticals B.V. | Duocarmycin adcs for use in the treatment of bladder cancer |
EP3092010B1 (en) | 2014-01-10 | 2018-07-11 | Synthon Biopharmaceuticals B.V. | Method for purifying cys-linked antibody-drug conjugates |
US10464955B2 (en) | 2014-02-28 | 2019-11-05 | Hangzhou Dac Biotech Co., Ltd. | Charged linkers and their uses for conjugation |
NZ739830A (en) | 2015-07-12 | 2021-12-24 | Hangzhou Dac Biotech Co Ltd | Bridge linkers for conjugation of cell-binding molecules |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
TW201808336A (en) | 2016-05-11 | 2018-03-16 | 賽諾菲公司 | Treatment regimen using anti-MUC1 maytansinoid immunoconjugate antibody for the treatment of tumors |
US20210308277A1 (en) | 2016-11-14 | 2021-10-07 | Hangzhou Dac Biotech Co., Ltd. | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers |
WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
EP4126833A1 (en) * | 2020-03-23 | 2023-02-08 | Helmholtz-Zentrum für Infektionsforschung GmbH | N-phenyl-3-mercaptopropanamide derivatives as metallo-beta-lactamase inhibitors for the treatment of bacterial infections |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5278324A (en) * | 1990-08-28 | 1994-01-11 | Virginia Tech Intellectual Properties, Inc. | Water soluble derivatives of taxol |
ES2149768T3 (en) * | 1992-03-25 | 2000-11-16 | Immunogen Inc | CONJUGATES OF BINDING AGENTS OF CELLS DERIVED FROM CC-1065. |
US5646298A (en) * | 1995-06-07 | 1997-07-08 | Procoron, Inc. | Cyclopropylindole prodrugs |
US6534660B1 (en) * | 2002-04-05 | 2003-03-18 | Immunogen, Inc. | CC-1065 analog synthesis |
US6756397B2 (en) * | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
-
2006
- 2006-03-07 EP EP06290379A patent/EP1832577A1/en not_active Withdrawn
-
2007
- 2007-03-05 PE PE2007000236A patent/PE20080691A1/en not_active Application Discontinuation
- 2007-03-06 EA EA200870327A patent/EA200870327A1/en unknown
- 2007-03-06 UY UY30190A patent/UY30190A1/en not_active Application Discontinuation
- 2007-03-06 JP JP2008557845A patent/JP2009529030A/en not_active Withdrawn
- 2007-03-06 WO PCT/IB2007/000521 patent/WO2007102069A1/en active Application Filing
- 2007-03-06 AU AU2007222123A patent/AU2007222123A1/en not_active Abandoned
- 2007-03-06 KR KR1020087021749A patent/KR20080106919A/en not_active Application Discontinuation
- 2007-03-06 EP EP07713102A patent/EP1993999A1/en not_active Withdrawn
- 2007-03-06 TW TW096107668A patent/TW200813028A/en unknown
- 2007-03-06 AR ARP070100932A patent/AR059767A1/en unknown
- 2007-03-06 DO DO2007000041A patent/DOP2007000041A/en unknown
- 2007-03-06 BR BRPI0708654-7A patent/BRPI0708654A2/en not_active Application Discontinuation
- 2007-03-06 CA CA002642870A patent/CA2642870A1/en not_active Abandoned
- 2007-03-06 MX MX2008011431A patent/MX2008011431A/en not_active Application Discontinuation
-
2008
- 2008-08-25 IL IL193673A patent/IL193673A0/en unknown
- 2008-09-04 US US12/204,082 patent/US8012978B2/en not_active Expired - Fee Related
- 2008-09-12 NO NO20083910A patent/NO20083910L/en not_active Application Discontinuation
- 2008-09-29 MA MA31261A patent/MA30322B1/en unknown
-
2011
- 2011-07-15 US US13/184,255 patent/US20110280890A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AR059767A1 (en) | 2008-04-30 |
EP1993999A1 (en) | 2008-11-26 |
KR20080106919A (en) | 2008-12-09 |
CA2642870A1 (en) | 2007-09-13 |
PE20080691A1 (en) | 2008-06-04 |
US20090028821A1 (en) | 2009-01-29 |
NO20083910L (en) | 2008-12-01 |
AU2007222123A1 (en) | 2007-09-13 |
IL193673A0 (en) | 2009-05-04 |
BRPI0708654A2 (en) | 2011-06-07 |
JP2009529030A (en) | 2009-08-13 |
US20110280890A1 (en) | 2011-11-17 |
UY30190A1 (en) | 2008-10-31 |
EP1832577A1 (en) | 2007-09-12 |
TW200813028A (en) | 2008-03-16 |
DOP2007000041A (en) | 2007-10-31 |
US8012978B2 (en) | 2011-09-06 |
MA30322B1 (en) | 2009-04-01 |
MX2008011431A (en) | 2008-09-22 |
WO2007102069A1 (en) | 2007-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200870327A1 (en) | IMPROVED PROCARE OF ANALOGUES SS-1065 | |
EA200870615A1 (en) | DERIVATIVES OF LEPTOMYCIN | |
EA200970648A1 (en) | CHEMICAL LINKS AND SPLITTED SUBSTRATES, AND THEIR CONJUGATES THEREOF | |
EA201000211A1 (en) | METHOD OF MODELING THE GPR119 RECEPTOR, CONNECTED WITH A G-PROTEIN, AND USED AT THIS CONNECTION | |
BRPI0410748B8 (en) | maytansinoid compounds, their pharmaceutical compositions, methods of esterification of maytansinoids, as well as methods for their production, and maytansinoid-cell binding agent conjugate | |
CR9947A (en) | PIRIMIDINIL BENZOTIOFENO COMPOUNDS | |
NZ620174A (en) | Protein kinase conjugates and inhibitors | |
DK1492526T3 (en) | Conjugated prodrugs of CC-1065 analogs | |
BR0309556A (en) | Pyrimidine-2,4,6-trione metalloproteinase inhibitors | |
CL2009000402A1 (en) | Substituted 2-amino-acetamide derived compounds; pharmaceutical composition; Useful in the treatment of lung diseases, rheumatic disease, autoimmune disease, among others. | |
EA201170921A1 (en) | PHARMACEUTICAL COMPOSITION | |
WO2008076270A3 (en) | Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof | |
WO2007005941A3 (en) | Liver targeted conjugates | |
EA201291050A1 (en) | COMBINATION OF MEDICINAL PROTECTIVES | |
PT2057139E (en) | Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs | |
ATE506340T1 (en) | 12-ARYL-PROSTAGLANDIN ANALOGUE | |
EA201170821A1 (en) | ENASTAURIN FOR CANCER TREATMENT | |
CY1113525T1 (en) | KATHEHINI TARGETING THERAPY S | |
TR201905548T4 (en) | Cancer stem cell targeted and drug resistant cancer therapy. | |
ATE474574T1 (en) | IMIDAZOAZEPHINONE COMPOUNDS | |
ATE487488T1 (en) | NOVEL ANTIBIOTIC COMPOSITIONS | |
AR063597A1 (en) | NEW SALT | |
EA200970355A1 (en) | NEW CRYSTAL (S) - (+) - 2- (2-CHLOROPHENYL) -2-HYDROXYETHYLKARBAMATE | |
RS51282B (en) | Compositions with enhanced elasticizing activity | |
PL2013273T3 (en) | Antiozonant blends |